UNSPSC 51131627: Cangrelor

This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6AQ1Y404U7. European Medicines Agency schedules Cangrelor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26448. Cangrelor generally arises in the molecular formula C17H25CL2F3N5O12P3S2. The term CANGRELOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule cangrelor under HS 29349990 and SITC 51579.

As of Q4 2014, CANGRELOR remains the US FDA Preferred Term for this commodity. Cangrelor bears US NLM identifiers UMLS ID C1121991 and NCI Concept Code C76395. SMILES: CLC(CL)(P(=O)(OP(=O)(OCC1OC(N2C3NC(SCCC(F)(F)F)NC(NCCSC)C3NC2)C(O)C1O)O)O)P(=O)(O)O.

UNSPSC 51131627 Cangrelor is a Commodity code that covers antiplatelet pharmaceutical products, specifically the P2Y12 platelet inhibitor cangrelor used in acute coronary syndrome and percutaneous coronary intervention settings. State and local governments procure this pharmaceutical under the code for use in public health facilities, correctional medical services, emergency medical systems, and other safety-net healthcare providers serving indigent or underinsured populations. The issuing bodies soliciting under this code typically include state departments of health and human services, county public health agencies and medical examiner offices, municipal hospitals and urgent care centers, and regional emergency medical services systems.

The single recent opportunity in the source—Sourcewell RFP #061626 posted May 12, 2026 with response due June 16, 2026—is misdirected and provides no actionable signal for cangrelor procurement. That solicitation explicitly targets law enforcement equipment and does not involve pharmaceutical acquisitions. Without relevant recent state and local opportunities in the source, the code shows no current activity that would inform pursuit decisions at this time.